

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Age and pregnancy were highlighted as protected characteristics. Inequalities may arise if different recommendations are made for children and pregnant women.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

All protected characteristics will be considered by committee when making its recommendations. However, the committee can only make recommendations within a technology's marketing authorisation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
--

No

Approved by Associate Director (name): ...Jasdeep Hayre

Date: 21 September 2023